

## Supporting Information

### Synthesis of substituted 4-, 5-, 6- and 7-azaindoles from aminopyridines *via* a cascade C-N cross-coupling/Heck reaction

Marina J. D. Pires,<sup>a</sup> Diogo L. Poeira,<sup>a</sup> Sara I. Purificação<sup>a</sup> and M. Manuel B. Marques<sup>a,\*</sup>

<sup>a</sup>LAQV@REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia  
Universidade Nova de Lisboa, Campus de Caparica  
2829-516 Caparica, Portugal  
E-mail: mmbmarques@fct.unl.pt

#### Table of contents

General information .....	2
General procedure for the cascade C-N cross-coupling/Heck with amino- <i>o</i> -bromopyridines .....	2
NMR spectra of azaindoles.....	7
Other information .....	22
( <i>E</i> )- <i>N</i> -(3-Bromopyridin-4-yl)-1-phenylethan-1-imine (3a).....	22
4-Bromo-1,2-dihydronaphthalene <sup>11</sup> .....	23
General procedure for <i>N</i> -arylation of amino- <i>o</i> -bromopyridines .....	24
NMR spectra of <i>N</i> -phenyl amino- <i>o</i> -bromopyridines.....	25
References .....	29

## General information

All reagents and solvents were acquired commercially and usually used without further purification. The solvents used during the reactions were dried and distilled using typical methods. Analytical TLC was performed on Merck Kieselgel GF 254, 0.2 mm plates supported on aluminum. Preparative TLC was performed using Merck Kieselgel 60GS<sub>254</sub> silica gel for TLC supported on a glass surface with the described eluent for each case. Column chromatography was performed using Merck Kieselgel 60A silica gel (70-200 mesh) or aluminium oxide 90 active neutral 0.063-0.200 mm (70-230 mesh ASTM from Merck) and the described eluent for each case.


Melting points were measured using a Reichert Thermovar melting point apparatus, equipped with a Kofler plate. Measured melting points were not corrected.

NMR spectra were acquired with Bruker ARX 400 or Bruker Avance III 400 spectrometers. <sup>1</sup>H-RMN and <sup>13</sup>C-RMN spectra were measured at 400 and 101 MHz, respectively. The samples were prepared on 5 or 3 mm NMR tubes using CDCl<sub>3</sub> or DMSO-d<sub>6</sub> as solvents and the corresponding trace CHCl<sub>3</sub> or DMSO as reference signals. The NMR signals are described with chemical shift (δ, in ppm), source of signal (R-H) and relative intensity of signal multiplicity (nH, with n being the number of protons) of NMR signals are described as singlet (s), broad singlet (br s), doublet of doublets (dd), triplet of doublets (td), doublet (d), triplet (t) and multiplet (m) with coupling constant (J) being given in Hz.

## General procedure for the cascade C-N cross-coupling/Heck with amino-*o*-bromopyridines

A sealed tube equipped with a magnetic stir bar was charged with Pd<sub>2</sub>dba<sub>3</sub> (4 mol %), XPhos (8 mol %), *t*-BuONa (3 equiv) and amino-*o*-bromopyridine (1 equiv). The tube was sealed with a suba-seal, evacuated and backfilled with nitrogen thrice. *t*-BuOH (c = 0.1 M) was then added, followed by the alkenyl bromide compound (1.5 equiv) and the reaction was stirred for 24 h at 110 °C. The solution was allowed to cool to room temperature and concentrated; the residue was then diluted on ethyl acetate and a saturated solution of NH<sub>4</sub>Cl was added. Aqueous layer was extracted several times (at least 4) until all the reaction products were recovered. Combined organic layers were dried with anhydrous sodium sulphate, filtered and concentrated. The desired product was isolated after purification by chromatography.<sup>1</sup>

### 2-Phenyl-5-azaindole (**4a**)<sup>1</sup>



**Purification:** Silica gel, dichloromethane/methanol with gradient

**Appearance:** White solid


**Yield:** 57% (19.1 mg of **4a** from 30 mg of starting 4-amino-3-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ:** 11.97 (s, NH, 1H), 8.82 (s, H<sub>5</sub>, 1H), 8.17 (d, *J* = 4.3 Hz, H<sub>6</sub>, 1H), 7.90 (d, *J* = 7.3 Hz, Ar-H<sub>14,10</sub>, 2H), 7.49 (t, *J* = 7.7 Hz, Ar-H<sub>13,11</sub>, 2H), 7.38 – 7.35 (m, Ar-H<sub>12</sub>, H<sub>7</sub>, 2H), 7.04 (s, H<sub>3</sub>, 1H)

**<sup>13</sup>C NMR (101 MHz, DMSO-d<sub>6</sub>) δ:** 142.95 (C<sub>5</sub>), 140.46 (C<sub>6</sub>), 140.36 (C<sub>8</sub>), 138.87 (C<sub>2</sub>), 131.42 (C<sub>9</sub>), 129.01 (C<sub>13,11</sub>), 128.08 (C<sub>12</sub>), 125.74 (C<sub>4</sub>), 125.36 (C<sub>10,14</sub>), 106.59 (C<sub>7</sub>), 97.57 (C<sub>3</sub>).

<sup>1</sup> **NOTE:** 2-Phenyl-4-azaindole (**4b**), 2-phenyl-6-azaindole (**4c**) and 7-azaindole (**4e**) when purified by silica gel tend to protonate; this was confirmed by NMR and with the addition of a drop of DBU (1,8-DiazabicycloUndec-7-ene) on the NMR tube, by comparison with the spectra reported for the azaindoles.

## 2-Phenyl-4-azaindole (**4b**)<sup>1</sup>



**Purification:** Neutral aluminium oxide, ethyl acetate/hexane (1:1)


**Appearance:** Yellow solid

**Yield:** 82% (27.5 mg of **4b** from 30 mg of starting 3-amino-2-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)**  $\delta$ : 11.79 (s, NH, 1H), 8.31 (d,  $J$  = 3.5 Hz,  $H_5$ , 1H), 7.93 (d,  $J$  = 7.4 Hz,  $H_{14,10}$ , 2H), 7.76 (d,  $J$  = 8.0 Hz,  $H_7$ , 1H), 7.50 (t,  $J$  = 7.6 Hz,  $H_{13,11}$ , 2H), 7.39 (t,  $J$  = 7.3 Hz,  $H_{12}$ , 1H), 7.10 (dd,  $J$  = 8.1, 4.6 Hz,  $H_6$ , 1H), 7.06 (s,  $H_3$ , 1H)

**<sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>)**  $\delta$ : 146.94 ( $C_4$ ), 142.87 ( $C_5$ ), 140.83 ( $C_2$ ), 131.49 ( $C_9$ ), 129.89 ( $C_8$ ), 128.99 ( $C_{13,11}$ ), 128.25 ( $C_{12}$ ), 125.39 ( $C_{10,14}$ ), 118.03 ( $C_7$ ), 116.63 ( $C_6$ ), 99.13 ( $C_3$ ).

## 2-Phenyl-6-azaindole (**4c**)<sup>1</sup>



**Purification:** Neutral aluminium oxide, ethyl acetate/hexane (1:1)

**Appearance:** Beige solid


**Yield:** 48% (26.7 mg of **4c** from 50 mg of starting 3-amino-4-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)**  $\delta$ : 12.02 (s, NH, 1H), 8.75 (s,  $H_7$ , 1H), 8.09 (d,  $J$  = 5.3 Hz,  $H_6$ , 1H), 7.94 (d,  $J$  = 7.3 Hz,  $H_{10,14}$ , 2H), 7.55 – 7.47 (m,  $H_5$ ,  $H_{11,13}$ , 3H), 7.40 (t,  $J$  = 7.3 Hz,  $H_{12}$ , 1H), 6.97 (s,  $H_3$ , 1H)

**<sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>)**  $\delta$ : 141.25 ( $C_2$ ), 138.26 ( $C_6$ ), 134.23 ( $C_7$ ), 133.43 ( $C_8$ )\*, 132.74 ( $C_4$ ), 131.30 ( $C_9$ ), 129.05 ( $C_{11,13}$ ), 128.56 ( $C_{12}$ ), 125.77 ( $C_{10,14}$ ), 114.41 ( $C_3$ ), 97.90 ( $C_3$ )

\*Observed on HMBC experiment, but it was not observed on <sup>13</sup>C.

## 2-Phenyl-7-azaindole (**4d**)<sup>2</sup>



**Purification:** Silica gel, dichloromethane/ethyl acetate with gradient


**Appearance:** Dark beige solid

**Yield:** 19% (10.7 mg of **4d** from 50 mg of starting 2-amino-3-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)**  $\delta$ : 12.13 (s, NH, 1H), 8.21 (d,  $J$  = 3.6 Hz,  $H_7$ , 1H), 7.98 – 7.89 (m,  $H_5$ ,  $H_{10,14}$ , 3H), 7.47 (t,  $J$  = 7.6 Hz,  $H_{11,13}$ , 2H), 7.35 (t,  $J$  = 7.3 Hz,  $H_{12}$ , 1H), 7.06 (dd,  $J$  = 7.7, 4.7 Hz,  $H_6$ , 1H), 6.93 (s,  $H_3$ , 1H)

**<sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>)**  $\delta$ : 149.66 ( $C_8$ ), 142.80 ( $C_7$ ), 138.20 ( $C_2$ ), 131.59 ( $C_9$ ), 128.90 ( $C_{11,13}$ ), 127.98 ( $C_{12}$ ), 127.80 ( $C_5$ ), 125.32 ( $C_{10,14}$ ), 120.90 ( $C_4$ ), 116.01 ( $C_6$ ), 97.08 ( $C_3$ ).

## 7-azaindole<sup>3</sup>



**Purification:** Silica gel, ethyl acetate/hexane (2:1) gave the protonated form


**Appearance:** Beige/yellow solid

**Yield:** 9% (3.2 mg of 7-azaindole from 50 mg of starting 2-amino-3-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$ : 8.29 (dd,  $J$  = 4.7, 1.2 Hz,  $H_7$ , 1H), 7.94 (dd,  $J$  = 7.8, 1.4 Hz,  $H_5$ , 1H), 7.34 (d,  $J$  = 3.5 Hz,  $H_3$ , 1H), 7.07 (dd,  $J$  = 7.8, 4.8 Hz,  $H_6$ , 1H), 6.49 (d,  $J$  = 3.5 Hz,  $H_2$ , 1H) and DBU

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$ : 148.56 ( $C_8$ ), 142.99 ( $C_7$ ), 128.98 ( $C_5$ ), 124.96 ( $C_2$ ), 120.32 ( $C_4$ ), 116.02 ( $C_6$ ), 100.88 ( $C_3$ ) and DBU.

### 3-Phenyl-4-azaindole<sup>4</sup>




**Purification:** Silica gel, hexane/ethyl acetate with gradient

**Appearance:** Beige solid

**Yield:** 2% (0.7 mg of 3-phenyl-4-azaindole from 30 mg of starting 3-amino-2-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, MeOD)  $\delta$ :** 8.38 (d,  $J$  = 4.2 Hz,  $H_5$ , 1H), 7.97 – 7.90 (m,  $H_{10,14}$ , 2H), 7.89 – 7.82 (m,  $H_7$ ,  $H_2$ , 2H), 7.41 (t,  $J$  = 7.7 Hz,  $H_{11,13}$ , 2H), 7.27 – 7.17 (m,  $H_{12}$ ,  $H_6$ , 2H).

### 2,3-Dimethyl-4-azaindole (**4e**)<sup>5</sup>



**Purification:** Silica gel, chloroform/methanol 3%


**Appearance:** Beige solid

**Yield:** 28% (7.1 mg of **4e** from 30 mg of starting 3-amino-2-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ :** 8.39 (dd,  $J$  = 4.6, 1.0 Hz,  $H_5$ , 1H), 8.15 (br s, NH, 1H), 7.51 (dd,  $J$  = 8.0, 1.0 Hz,  $H_7$ , 1H), 7.00 (dd,  $J$  = 8.0, 4.8 Hz,  $H_6$ , 1H), 2.42 (s, 3x $H_9$ , 3H), 2.32 (s, 3x $H_{10}$ , 3H)

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$ :** 146.94 ( $C_4$ ), 142.10 ( $C_5$ ), 135.54 ( $C_2$ ), 128.56 ( $C_8$ ), 117.04 ( $C_7$ ), 115.82 ( $C_6$ ), 108.20 ( $C_3$ ), 12.26( $C_9$ ), 7.59 ( $C_{10}$ ).

### 2-Ethyl-4-azaindole (**4f**)<sup>6</sup>



**Purification:** Neutral aluminium oxide, hexane/ethyl acetate with gradient


**Appearance:** Pale brown solid

**Yield:** 21% (9 mg of **4f** from 50 mg of starting 3-amino-2-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ :** 9.18 (br s, NH, 1H), 8.38 (dd,  $J$  = 4.6, 1.2 Hz,  $H_5$ , 1H), 7.57 (d,  $J$  = 8.0 Hz,  $H_7$ , 1H), 7.02 (dd,  $J$  = 8.1, 4.8 Hz,  $H_6$ , 1H), 6.45 (s,  $H_3$ , 1H), 2.85 (q,  $J$  = 7.5 Hz,  $H_9$ , 2H), 1.36 (t,  $J$  = 7.6 Hz,  $H_{10}$ , 3H)

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$ :** 147.32 ( $C_4$ ), 146.23 ( $C_2$ ), 142.42 ( $C_5$ ), 129.25 ( $C_8$ ), 117.62 ( $C_7$ ), 115.90 ( $C_6$ ), 99.51 ( $C_3$ ), 21.97 ( $C_9$ ), 13.17 ( $C_{10}$ ).

### 2-Ethyl-5-azaindole (**4g**)



**Purification:** Neutral aluminium oxide, chloroform 100%


**Appearance:** Brown solid

**Yield:** 23% (9.6 mg of **4g** from 50 mg of starting 4-amino-3-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ :** 9.39 (br s, NH, 1H), 8.83 (s,  $H_5$ , 1H), 8.24 (d,  $J$  = 5.7 Hz,  $H_6$ , 1H), 7.23 (d,  $J$  = 5.7 Hz,  $H_7$ , 1H), 6.33 (s,  $H_3$ , 1H), 2.84 (td,  $J$  = 14.5, 7.3 Hz,  $H_9$ , 2H), 1.37 (t,  $J$  = 7.6 Hz,  $H_{10}$ , 3H)

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$ :** 143.13 ( $C_2$ ), 142.39 ( $C_5$ ), 140.14 ( $C_8$ ), 140.03 ( $C_6$ ), 126.02 ( $C_4$ ), 106.13 ( $C_7$ ), 97.69 ( $C_3$ ), 21.51 ( $C_9$ ), 13.21 ( $C_{10}$ ).

### 2-Ethyl-6-azaindole (**4h**)<sup>7</sup>



**Purification:** Neutral aluminium oxide, chloroform/methanol with gradient


**Appearance:** Brown solid

**Yield:** 22% (9.1 mg of **4h** from 50 mg of starting 3-amino-4-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ:** 8.75 (s, *H*<sub>7</sub>, 1H), 8.18 (d, *J* = 5.5 Hz, *H*<sub>6</sub>, 1H), 7.45 (d, *J* = 5.2 Hz, *H*<sub>5</sub>, 1H), 6.28 (s, *H*<sub>3</sub>, 1H), 2.88 (q, *J* = 7.6 Hz, *H*<sub>9</sub>, 2H), 1.39 (t, *J* = 7.6 Hz, *H*<sub>10</sub>, 3H)

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ:** 147.00 (C<sub>2</sub>), 137.95 (C<sub>6</sub>), 134.24 (C<sub>8</sub>), 133.64 (C<sub>4</sub>), 132.74 (C<sub>7</sub>), 114.63 (C<sub>5</sub>), 98.40 (C<sub>3</sub>), 21.77 (C<sub>9</sub>), 13.23 (C<sub>10</sub>).

### 2-Ethyl-7-azaindole (**4i**)<sup>8</sup>



**Purification:** Neutral aluminium oxide, hexane/ethyl acetate with gradient followed by PTLC using dichloromethane/ethyl acetate (10%)


**Appearance:** Brown solid

**Yield:** 15% (6.5 mg of **4i** from 50 mg of starting 2-amino-3-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ:** 10.84 (br s, NH, 1H), 8.21 (d, *J* = 3.6 Hz, *H*<sub>7</sub>, 1H), 7.83 (dd, *J* = 7.7, 1.0 Hz, *H*<sub>5</sub>, 1H), 7.03 (dd, *J* = 7.7, 4.8 Hz, *H*<sub>6</sub>, 1H), 6.20 (s, *H*<sub>3</sub>, 1H), 2.89 (q, *J* = 7.5 Hz, *H*<sub>9</sub>, 2H), 1.40 (dd, *J* = 18.9, 11.3 Hz, *H*<sub>10</sub>, 3H)

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ:** 149.14 (C<sub>8</sub>), 142.86 (C<sub>2</sub>), 141.05 (C<sub>7</sub>), 127.75 (C<sub>5</sub>), 121.78 (C<sub>4</sub>), 115.76 (C<sub>6</sub>), 96.74 (C<sub>3</sub>), 21.92 (C<sub>9</sub>), 13.24 (C<sub>10</sub>).

### 6,11-Dihydro-5*H*-benzo[*g*]pyrido[3,2-*b*]indole (**4j**)<sup>5</sup>



**Purification:** Neutral aluminium oxide, dichloromethane followed by PTLC using chloroform/methanol (7%)

**Appearance:** White solid

**Yield:** 85% (32.5 mg of **4j** from 30 mg of starting 3-amino-2-bromopyridine)


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ:** 8.82 (br s, NH, 1H), 8.44 (d, *J* = 3.8 Hz, *H*<sub>5</sub>, 1H), 7.67 (d, *J* = 7.1 Hz, *H*<sub>7</sub>, 1H), 7.45 (d, *J* = 7.1 Hz, *H*<sub>15</sub>, 1H), 7.32 – 7.19 (m, *H*<sub>14</sub>, *H*<sub>13</sub>, *H*<sub>12</sub>, 3H + CDCl<sub>3</sub>), 7.09 (dd, *J* = 8.1, 4.7 Hz, *H*<sub>6</sub>, 1H), 3.17 – 3.04 (m, 2x *H*<sub>9</sub>, 2x *H*<sub>10</sub>, 4H)

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ:** 144.83 (C<sub>4</sub>), 143.02 (C<sub>5</sub>), 137.75 (C<sub>2</sub>), 137.11 (C<sub>11</sub>), 130.60 (C<sub>8</sub>), 128.94 (Ar-C), 128.29 (C<sub>16</sub>), 128.10 (Ar-C), 126.86 (Ar-C), 120.40 (C<sub>15</sub>), 118.38 (C<sub>7</sub>), 116.95 (C<sub>6</sub>), 112.41 (C<sub>3</sub>), 29.47 (CH<sub>2</sub>), 18.74 (CH<sub>2</sub>)

**IR (cm<sup>-1</sup>) (NaCl):** 3050, 2925, 2849, 1466

**M.p.:** 228-230 °C (lit.: 254-256 °C).

### 6,11-Dihydro-5*H*-benzo[*g*]pyrido[4,3-*b*]indole (**4k**)<sup>5</sup>




**Purification:** PTLC using chloroform/methanol (7%)

**Appearance:** Beige solid

**Yield:** 19% (7.1 mg of **4k** from 30 mg of starting 4-amino-3-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$ : 8.84 (s, *H*<sub>5</sub>, 1H), 8.24 (d, *J* = 3.8 Hz, *H*<sub>6</sub>, 1H), 7.45 (d, *J* = 7.0 Hz, *H*<sub>15</sub>, 1H), 7.36 – 7.17 (m, *H*<sub>14</sub>, *H*<sub>13</sub>, *H*<sub>12</sub>, *H*<sub>7</sub>, 4H + CDCl<sub>3</sub>), 3.12 – 2.97 (m, 2*xH*<sub>9</sub>, 2*xH*<sub>10</sub>, 4H)  
**IR (cm<sup>-1</sup>) (NaCl)**: 2964, 2915, 2853, 1461  
**M.p.**: 243-245 °C (lit.: 250-252 °C).

**6,11-Dihydro-5*H*-benzo[*g*]pyrido[3,4-*b*]indole (4l)**



**Purification**: Neutral aluminium oxide, hexane/ethyl acetate with gradient until chloroform/methanol (10%) followed by PTLC using chloroform/methanol (7%)

**Appearance**: Beige solid

**Yield**: 28% (14.3 mg of **4l** from 40 mg of starting 3-amino-4-bromopyridine)


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$ : 8.93 (s, *H*<sub>7</sub>, 1H), 8.05 (d, *J* = 5.3 Hz, *H*<sub>6</sub>, 1H), 7.88 – 7.78 (m, *H*<sub>15</sub>, 1H), 7.41 (d, *J* = 5.6 Hz, *H*<sub>5</sub>, 1H), 7.24 – 7.12 (m, *H*<sub>14</sub>, *H*<sub>13</sub>, *H*<sub>12</sub>, 3H + CDCl<sub>3</sub>), 3.03 – 2.85 (m, 2*xH*<sub>9</sub>, 2*xH*<sub>10</sub>, 4H)

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$ : 141.03 (C<sub>2</sub>), 137.68 (C<sub>11</sub>), 134.14 (C<sub>6</sub>), 134.02 (C<sub>8</sub>), 132.93 (C<sub>4</sub>), 131.15 (C<sub>7</sub>), 128.73 (C<sub>16</sub>), 128.47 (C-Ar), 127.78 (C-Ar), 127.16 (C-Ar), 123.10 (C<sub>15</sub>), 113.62 (C<sub>5</sub>), 111.01 (C<sub>3</sub>), 29.28 (CH<sub>2</sub>), 19.35 (CH<sub>2</sub>).

**IR (cm<sup>-1</sup>) (NaCl)**: 3157, 3059, 2934, 2898, 2840, 1644, 1545, 1470, 1434

**M.p.**: 149-151 °C.

**6,11-Dihydro-5*H*-benzo[*g*]pyrido[2,3-*b*]indole (4m)<sup>9</sup>**



**Purification**: Neutral aluminium oxide, hexane/ethyl acetate with gradient followed by PTLC using cyclohexane/ethyl acetate 3:1

**Appearance**: White solid


**Yield**: 21% (10.6 mg of **4m** from 40 mg of starting 2-amino-3-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$ : 8.28 (d, *J* = 3.9 Hz, *H*<sub>7</sub>, 1H), 7.82 (dd, *J* = 8.0, 1.2 Hz, *H*<sub>5</sub>, 1H), 7.56 (d, *J* = 7.3 Hz, *H*<sub>15</sub>, 1H), 7.33 – 7.16 (m, *H*<sub>12</sub>, *H*<sub>13</sub>, *H*<sub>14</sub>, 3H + CDCl<sub>3</sub>), 7.05 (dd, *J* = 7.7, 4.8 Hz, *H*<sub>6</sub>, 1H), 3.01 – 2.92 (m, 2*xH*<sub>9</sub>, 2*xH*<sub>10</sub>, 4H) and DBU

**IR (cm<sup>-1</sup>) (NaCl)**: 3147, 3121, 3047, 2920, 2893, 2848, 1581, 1470 (protonated form)

**M.p.**: 191-193 °C (protonated form) (lit.: 210-211 °C).

**1,2-Diphenyl-4-azaindole<sup>10</sup>**





**Purification**: Neutral aluminium oxide, hexane/ethyl acetate with gradient followed by PTLC using hexane/ethyl acetate 2:1



**Appearance**: Beige solid

**Yield**: 5% (1.6 mg of 1,2- diphenyl-4-azaindole from 30 mg of starting 3-amino-2-bromopyridine)



**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$ : 8.51 (d, *J* = 3.5 Hz, *H*<sub>5</sub>, 1H), 7.57 (d, *J* = 8.1 Hz, *H*<sub>7</sub>, 1H), 7.46 – 7.38 (m, *Ar-H*, 3H), 7.28 – 7.22 (m, *Ar-H*, 7H + CDCl<sub>3</sub>), 7.11 (dd, *J* = 8.0, 4.4 Hz, *H*<sub>6</sub>, 1H), 7.02 (s, *H*<sub>3</sub>, 1H).



# NMR spectra of azaindoles


























































## Other information

### (*E*)-*N*-(3-Bromopyridin-4-yl)-1-phenylethan-1-imine (**3a**)

This imine was isolated with 50% yield (24 mg) from the same reaction procedure previously mentioned for the 2-phenyl-5-azaindole synthesis, when performed in toluene using DavePhos as ligand, starting from 30 mg of 4-amino-3-bromopyridine.




**Purification:** Neutral aluminium oxide, hexane/ethyl acetate with gradient


**Appearance:** Yellow Oil

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$ : 8.68 (s, *H*<sub>3</sub>, 1H), 8.41 (d, *J* = 4.1 Hz, *H*<sub>4</sub>, 1H), 7.99 (d, *J* = 6.2 Hz, *H*<sub>9,13</sub>, 2H), 7.55 – 7.46 (m, *H*<sub>10,12</sub>, *H*<sub>11</sub>, 3H), 6.75 (d, *J* = 5.0 Hz, *H*<sub>5</sub>, 1H), 2.23 (s, *H*<sub>7</sub>, 3H).


**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$ : 167.67 (C<sub>6</sub>), 156.85 (C<sub>1</sub>), 152.38 (C<sub>3</sub>), 148.89 (C<sub>4</sub>), 137.88 (C<sub>8</sub>), 131.61 (C<sub>11</sub>), 128.72 (C<sub>10,12</sub>), 127.70 (C<sub>9,13</sub>), 115.46 (C<sub>5</sub>), 112.22 (C<sub>2</sub>), 18.73 (C<sub>7</sub>).

**IR (cm<sup>-1</sup>) (NaCl):** 1643 (imine).





#### 4-Bromo-1,2-dihydronaphthalene<sup>11</sup>



1,2-Dihydronaphthalene (1.5 mmol) was dissolved in dichloromethane (7 mL), then Br<sub>2</sub> (2 equiv) was added dropwise at 0 °C. After 2 h 30 min the reaction the reaction was quenched with a saturated aq. solution of sodium thiosulphate (7 mL) and stirred for 15 minutes. The organic layer was extracted and the aqueous layer was washed twice with dichloromethane. The combined organic layers were washed twice with a saturated aq. solution of sodium thiosulphate and brine; then dried over anhydrous MgSO<sub>4</sub>, filtered and dried under vacuum. The product 1,2-dibromo-1,2,3,4-tetrahydronaphthalene (436 mg) was used for the next step without further purification.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.35 – 7.08 (m, 4H), 5.68 – 5.64 (m, 1H), 4.98 – 4.90 (m, 1H), 3.28 (ddd, *J* = 17.7, 11.9, 6.1 Hz, 1H), 2.95 (dd, *J* = 17.4, 5.8 Hz, 1H), 2.90 – 2.76 (m, 1H), 2.26 – 2.14 (m, 1H).<sup>12</sup>


To a round-bottom flask charged with piperidine (3 equiv) at 0 °C was added a solution of the crude product 1,2-dibromo-1,2,3,4-tetrahydronaphthalene (400 mg) in dry toluene (0.8 mL) dropwise for 2 hours (about 66 μL/10 minutes). The reaction was left overnight at room temperature and then heated for 2 h 30 min at 90 °C. The reaction crude was neutralized by slowly adding this mixture to a solution of 1 M HCl (3.45 mL). The organic layer was separated and the aqueous was washed thrice with Et<sub>2</sub>O. The combined organic layers were washed with water, then dried over anhydrous MgSO<sub>4</sub>, filtered and dried under vacuum. The desired product was isolated after a fast purification by a large and short column chromatography (silica gel, hexane) and attained as unstable colourless oil in 67% yield (192 mg).<sup>13</sup>

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.54 (d, *J* = 7.5 Hz, 1H), 7.25 – 7.14 (m, 2H), 7.07 (d, *J* = 7.1 Hz, 1H), 6.42 (t, *J* = 4.8 Hz, 1H), 2.82 (t, *J* = 8.0 Hz, 2H), 2.34 (td, *J* = 8.1, 4.9 Hz, 2H).<sup>11</sup>

## General procedure for *N*-arylation of amino-*o*-bromopyridines

A sealed tube equipped with a magnetic stir bar was charged with Pd<sub>2</sub>dba<sub>3</sub> (4 mol %), XantPhos (8 mol %), *t*-BuONa (2 equiv) and amino-*o*-bromopyridine (1 equiv) and dry toluene (*c* = 0.2 M), followed by iodobenzene (1.2 equiv). The reaction was stirred for 6 hours at 110 °C. The crude reaction product was filtered through a celite pad. The desired product was isolated after purification by column chromatography (silica gel, EtOAc: hexane with gradient).

### 3-Bromo-*N*-phenylpyridin-4-amine (5a)<sup>14</sup>




**Appearance:** Beige solid

**Yield:** 87% (124.8 mg of **5a** from 100 mg of starting 4-amino-3-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ:** 8.48 (s, *H*<sub>3</sub>, 1H), 8.13 (d, *J* = 5.6 Hz, *H*<sub>4</sub>, 1H), 7.41 (t, *J* = 7.8 Hz, *H*<sub>10,8</sub>, 2H), 7.31 – 7.15 (m, *H*<sub>7,11,9</sub>, 3H), 6.91 (d, *J* = 5.7 Hz, *H*<sub>5</sub>, 1H), 6.57 (s, NH, 1H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ:** 151.43 (C<sub>3</sub>), 148.68 (C<sub>4</sub>), 148.31 (C<sub>1</sub>), 138.47 (C<sub>6</sub>), 129.87 (C<sub>8,10</sub>), 125.69 (C<sub>9</sub>), 123.56 (C<sub>7,11</sub>), 108.42 (C<sub>2</sub>), 107.83 (C<sub>5</sub>).

### 2-Bromo-*N*-phenylpyridin-3-amine (5b)<sup>14</sup>




**Appearance:** Yellow solid

**Yield:** 99% (143.4 mg of **5b** from 100 mg of starting 3-amino-2-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ:** 7.84 (dd, *J* = 4.5, 1.5 Hz, *H*<sub>3</sub>, 1H), 7.42 (dd, *J* = 8.1, 1.5 Hz, *H*<sub>5</sub>, 1H), 7.35 (t, *J* = 7.9 Hz, *H*<sub>10,8</sub>, 2H), 7.18 – 7.04 (m, *H*<sub>11,7</sub>, *H*<sub>9</sub>, *H*<sub>4</sub>, 4H), 6.14 (br s, NH, 1H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ:** 140.04 (C<sub>6</sub>), 139.85 (C<sub>3</sub>), 139.48 (C<sub>1</sub>), 131.71 (C<sub>2</sub>), 129.77 (C<sub>10,8</sub>), 124.05 (C<sub>9</sub>), 123.45 (C<sub>4</sub>), 121.32 (C<sub>11,7</sub>), 121.23 (C<sub>5</sub>).

### 4-Bromo-*N*-phenylpyridin-3-amine (5c)<sup>14</sup>




**Appearance:** Beige solid

**Yield:** 79% (113.4 mg of **5c** from 100 mg of starting 3-amino-4-bromopyridine)

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ:** 8.50 (s, *H*<sub>5</sub>, 1H), 7.92 (d, *J* = 5.1 Hz, *H*<sub>4</sub>, 1H), 7.45 (d, *J* = 5.1 Hz, *H*<sub>3</sub>, 1H), 7.35 (t, *J* = 7.9 Hz, *H*<sub>10,8</sub>, 2H), 7.18 (d, *J* = 7.7 Hz, *H*<sub>11,7</sub>, 2H), 7.10 (t, *J* = 7.4 Hz, *H*<sub>9</sub>, 1H), 5.96 (s, NH, 1H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ:** 141.29 (C<sub>4</sub>), 140.58 (C<sub>6</sub>), 138.91 (C<sub>1</sub>), 137.95 (C<sub>5</sub>), 129.85 (C<sub>10,8</sub>), 127.74 (C<sub>3</sub>), 123.83 (C<sub>9</sub>), 121.11 (C<sub>2</sub>), 120.73 (C<sub>11,7</sub>).

### 3-Bromo-*N*-phenylpyridin-2-amine (5d)<sup>14</sup>



**Appearance:** Oil



**Yield:** 94% (142.8 mg of **5d** from 100 mg of starting 2-amino-3-bromopyridine)



**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ:** 8.17 (dd, *J* = 4.7, 1.3 Hz, *H*<sub>5</sub>, 1H), 7.74 (dd, *J* = 7.7, 1.4 Hz, *H*<sub>3</sub>, 1H), 7.63 (d, *J* = 7.8 Hz, *H*<sub>11,7</sub>, 2H), 7.36 (t, *J* = 7.9 Hz, *H*<sub>10,8</sub>, 2H), 7.11 – 6.99 (m, *H*<sub>9</sub>, NH, 2H), 6.64 (dd, *J* = 7.7, 4.8 Hz, *H*<sub>4</sub>, 1H).





**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ:** 151.96 (C<sub>1</sub>), 146.52 (C<sub>5</sub>), 140.33 (C<sub>3</sub>), 139.81 (C<sub>6</sub>), 129.03 (C<sub>10,8</sub>), 122.98 (C<sub>9</sub>), 120.14 (C<sub>11,7</sub>), 115.72 (C<sub>4</sub>), 106.47 (C<sub>2</sub>).





# NMR spectra of *N*-phenyl amino-*o*-bromopyridines









## References

1. S. H. Spergel; D. R. Okoro and W. Pitts, *J. Org. Chem.*, 2010, **75**, 5316–5319.
2. Y. Ma; S. Breslin; I. Keresztes; E. Lobkovsky and D. B. Collum, *J. Org. Chem.*, 2008, **73**, 9610–9618.
3. M. P. Huestis and K. Fagnou, *Org. Lett.*, 2009, **11**, 1357–1360.
4. S. Llona-Minguez; M. Desroses; A. Ghassemian; S. A. Jacques; L. Eriksson; R. Isacksson; T. Koolmeister; P. Stenmark; M. Scobie and T. Helleday, *Chem. Eur. J.*, 2015, **21**, 7394–7398.
5. A. H. Kelly and J. Parrick, *J. Chem. Soc. C*, 1970, 303–307.
6. R. Beugelmans; B. Boudet and L. Quintero, *Tetrahedron Lett.*, 1980, **21**, 1943–1944.
7. National Center for Biotechnology Information. PubChem Compound Database; CID=68345838, <https://pubchem.ncbi.nlm.nih.gov/compound/68345838> (accessed May 10, 2016).
8. P. Graczyk, Process for preparing 7-azaindoles. Google Patents: 2004.
9. A. H. Kelly and J. Parrick, *Can. J. Chemistry*, 1966, **44**, 2455–2459.
10. S. M. Crawford; C. B. Lavery and M. Stradiotto, *Chem. Eur. J.*, 2013, **19**, 16760–16771.
11. D. P. Ojha and K. R. Prabhu, *Org. Lett.*, 2015, **17**, 18–21.
12. K. Bhandari; V. L. Sharma; C. M. Singh; G. Shankar and H. K. Singh, *Indian J. Chem. B*, 2000, **39**, 468–471.
13. A. G. M. Willems; U. K. Pandit and H. O. Huisman, *Recl. Trav. Chim. Pays-Bas*, 1965, **84**, 389–392.
14. T. Iwaki; A. Yasuhara and T. Sakamoto, *J. Chem. Soc., Perkin Trans. 1*, 1999, 1505–1510.